Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address behavioral and cognitive deficits in individuals with...
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | -0.054 | -17.5324675325 | 0.308 | 0.308 | 0.258 | 2250 | 0.30244444 | DE |
26 | 0.018 | 7.62711864407 | 0.236 | 0.316 | 0.236 | 2922 | 0.28293048 | DE |
52 | -0.014 | -5.22388059701 | 0.268 | 0.316 | 0.218 | 2589 | 0.27501809 | DE |
156 | -0.014 | -5.22388059701 | 0.268 | 0.316 | 0.218 | 2589 | 0.27501809 | DE |
260 | -0.014 | -5.22388059701 | 0.268 | 0.316 | 0.218 | 2589 | 0.27501809 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.